help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blutt, S. E.
Right arrow Articles by Weigel, N. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blutt, S. E.
Right arrow Articles by Weigel, N. L.
Endocrinology Vol. 138, No. 4 1491-1497
Copyright © 1997 by The Endocrine Society

ARTICLES

1,25-Dihydroxyvitamin D3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G11

Sarah E. Blutt, Elizabeth A. Allegretto, J. Wesley Pike and Nancy L. Weigel

Department of Cell Biology, Baylor College of Medicine (S.E.B., N.L.W.), Houston, Texas 77030; Ligand Pharmaceuticals (E.A.A.) San Diego, California 92121; and the Department of Molecular and Cellular Physiology, University of Cincinnati (J.W.P.), Cincinnati, Ohio 45267

Address all correspondence and requests for reprints to: Dr. Nancy L. Weigel, Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030. E-mail: nweigel{at}bcm.tmc.edu

Recent studies have suggested that the active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3, can inhibit the growth and/or induce the differentiation of a variety of cell types and that these characteristics might be useful in the treatment of some cancers. Retinoids also promote the differentiation and inhibit the growth of some cells. That the vitamin D receptor acts as a heterodimer with the retinoid X receptor (RXR) suggests that there may be functional interactions between 1,25-dihydroxyvitamin D3 and retinoids. In this study, we show that the combination of 1,25-dihydroxyvitamin D3 and 9-cis retinoic acid synergistically inhibits the growth of LNCaP prostate cancer cells. That this effect is mediated by RXR rather than retinoic acid receptors was shown using RXR- and retinoic acid receptor-specific ligands. The vitamin D3 analog, EB1089, inhibited growth more effectively than 1,25-dihydroxyvitamin D3 and also acted synergistically with 9-cis-retinoic acid. These treatments caused cells to accumulate in the G1 phase of the cell cycle, suggesting that 1,25-dihydroxyvitamin D3 can regulate one or more factors critical for the G1/S transition.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
J. Kaeding, J. Belanger, P. Caron, M. Verreault, A. Belanger, and O. Barbier
Calcitrol (1{alpha},25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells
Mol. Cancer Ther., February 1, 2008; 7(2): 380 - 390.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. L. Eisinger, L. D. Nadauld, D. N. Shelton, S. M. Prescott, D. M. Stafforini, and D. A. Jones
Retinoic Acid Inhibits beta-Catenin through Suppression of Cox-2: A ROLE FOR TRUNCATED ADENOMATOUS POLYPOSIS COLI
J. Biol. Chem., October 5, 2007; 282(40): 29394 - 29400.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S Humez, M Monet, G Legrand, G Lepage, P Delcourt, and N Prevarskaya
Epidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 181 - 195.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson
Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Endocr. Rev., December 1, 2005; 26(7): 898 - 915.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
G. E. Avila, X. Zheng, X. X. Cui, A. D. Ryan, A. Hansson, J. Suh, A. B. Rabson, R. L. Chang, W. J. Shih, Y. Lin, et al.
Inhibitory Effects of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans Retinoic Acid on the Growth of Cultured Human Pancreas Cancer Cells and Pancreas Tumor Xenografts in Immunodeficient Mice
J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 170 - 187.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H.-Y. Lee, Y. S. Chang, J.-Y. Han, D. D. Liu, J. J. Lee, R. Lotan, M. R. Spitz, and W. K. Hong
Effects of 9-cis-Retinoic Acid on the Insulin-Like Growth Factor Axis in Former Smokers
J. Clin. Oncol., July 1, 2005; 23(19): 4439 - 4449.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Liu, K.-W. Lee, H. Li, L. Ma, G. L. Lin, R. A.S. Chandraratna, and P. Cohen
Combination Therapy of Insulin-Like Growth Factor Binding Protein-3 and Retinoid X Receptor Ligands Synergize on Prostate Cancer Cell Apoptosis In vitro and In vivo
Clin. Cancer Res., July 1, 2005; 11(13): 4851 - 4856.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-Y. Han, D. D. Liu, J. J. Lee, J. Kurie, R. Lotan, W. K. Hong, and H.-Y. Lee
9-cis-Retinoic Acid Treatment Increases Serum Concentrations of {alpha}-Tocopherol in Former Smokers
Clin. Cancer Res., March 15, 2005; 11(6): 2305 - 2311.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Jiang, J. Bao, P. Li, S. V. Nicosia, and W. Bai
Induction of Ovarian Cancer Cell Apoptosis by 1,25-Dihydroxyvitamin D3 through the Down-regulation of Telomerase
J. Biol. Chem., December 17, 2004; 279(51): 53213 - 53221.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. Narayanan, V. A. T. Sepulveda, M. Falzon, and N. L. Weigel
The Functional Consequences of Cross-talk between the Vitamin D Receptor and ERK Signaling Pathways Are Cell-specific
J. Biol. Chem., November 5, 2004; 279(45): 47298 - 47310.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Li, C. Li, X. Zhao, X. Zhang, S. V. Nicosia, and W. Bai
p27Kip1 Stabilization and G1 Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through Down-regulation of Cyclin E/Cyclin-dependent Kinase 2 and Skp1-Cullin-F-box Protein/Skp2 Ubiquitin Ligase
J. Biol. Chem., June 11, 2004; 279(24): 25260 - 25267.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. Peng, P. J. Malloy, and D. Feldman
Identification of a Functional Vitamin D Response Element in the Human Insulin-Like Growth Factor Binding Protein-3 Promoter
Mol. Endocrinol., May 1, 2004; 18(5): 1109 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
L. V. Stewart and N. L. Weigel
Vitamin D and Prostate Cancer
Experimental Biology and Medicine, April 1, 2004; 229(4): 277 - 284.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zheng, R. L. Chang, X.-X. Cui, G. E. Avila, S. Lee, Y. P. Lu, Y. R. Lou, W. J. Shih, Y. Lin, K. Reuhl, et al.
Inhibitory Effect of 12-O-Tetradecanoylphorbol-13-acetate Alone or in Combination with All-trans-Retinoic Acid on the Growth of LNCaP Prostate Tumors in Immunodeficient Mice
Cancer Res., March 1, 2004; 64(5): 1811 - 1820.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
F. Jiang, P. Li, A. J. Fornace Jr., S. V. Nicosia, and W. Bai
G2/M Arrest by 1,25-Dihydroxyvitamin D3 in Ovarian Cancer Cells Mediated through the Induction of GADD45 via an Exonic Enhancer
J. Biol. Chem., November 28, 2003; 278(48): 48030 - 48040.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. S. Yang and K. L. Burnstein
Vitamin D Inhibits G1 to S Progression in LNCaP Prostate Cancer Cells through p27Kip1 Stabilization and Cdk2 Mislocalization to the Cytoplasm
J. Biol. Chem., November 21, 2003; 278(47): 46862 - 46868.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
I. Audo, S. R. Darjatmoko, C. L. Schlamp, J. M. Lokken, M. J. Lindstrom, D. M. Albert, and R. W. Nickells
Vitamin D Analogues Increase p53, p21, and Apoptosis in a Xenograft Model of Human Retinoblastoma
Invest. Ophthalmol. Vis. Sci., October 1, 2003; 44(10): 4192 - 4199.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
N. Ikeda, H. Uemura, H. Ishiguro, M. Hori, M. Hosaka, S. Kyo, K.-i. Miyamoto, E. Takeda, and Y. Kubota
Combination Treatment with 1{alpha},25-Dihydroxyvitamin D3 and 9-cis-Retinoic Acid Directly Inhibits Human Telomerase Reverse Transcriptase Transcription in Prostate Cancer Cells
Mol. Cancer Ther., August 1, 2003; 2(8): 739 - 746.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
C. Spitzweg, I. V. Scholz, E. R. Bergert, D. J. Tindall, C. Y. F. Young, B. Goke, and J. C. Morris
Retinoic Acid-Induced Stimulation of Sodium Iodide Symporter Expression and Cytotoxicity of Radioiodine in Prostate Cancer Cells
Endocrinology, August 1, 2003; 144(8): 3423 - 3432.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
D. M. Peehl, A. V. Krishnan, and D. Feldman
Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer
J. Nutr., July 1, 2003; 133(7): 2461S - 2469.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. C. Polek, L. V. Stewart, E. J. Ryu, M. B. Cohen, E. A. Allegretto, and N. L. Weigel
p53 Is Required for 1,25-Dihydroxyvitamin D3-Induced G0 Arrest But Is Not Required for G1 Accumulation or Apoptosis of LNCaP Prostate Cancer Cells
Endocrinology, January 1, 2003; 144(1): 50 - 60.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
J. M. Alfaro, B. Fraile, M. V. T. Lobo, M. Royuela, R. Paniagua, and M. I. Arenas
Immunohistochemical Detection of the Retinoid X Receptors {alpha}, {beta}, and {gamma} in Human Prostate
J Androl, January 1, 2003; 24(1): 113 - 119.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
F. Richter, A. Joyce, F. Fromowitz, S. Wang, J. Watson, R. Watson, R. J. Irwin Jr, and H. F. S. Huang
Immunohistochemical Localization of the Retinoic Acid Receptors in Human Prostate
J Androl, November 1, 2002; 23(6): 830 - 838.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. S. Prins, W. Y. Chang, Y. Wang, and R. B. van Breemen
Retinoic Acid Receptors and Retinoids Are Up-Regulated in the Developing and Adult Rat Prostate by Neonatal Estrogen Exposure
Endocrinology, September 1, 2002; 143(9): 3628 - 3640.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Huang, W. C. Powell, A. C. Khodavirdi, J. Wu, T. Makita, R. D. Cardiff, M. B. Cohen, H. M. Sucov, and P. Roy-Burman
Prostatic Intraepithelial Neoplasia in Mice with Conditional Disruption of the Retinoid X Receptor{alpha} Allele in the Prostate Epithelium
Cancer Res., August 15, 2002; 62(16): 4812 - 4819.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Shah, M. J. Pishvaian, V. Easwaran, P. H. Brown, and S. W. Byers
The Role of Cadherin, beta -Catenin, and AP-1 in Retinoid-regulated Carcinoma Cell Differentiation and Proliferation
J. Biol. Chem., July 5, 2002; 277(28): 25313 - 25322.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Kim, R. M. Adam, and M. R. Freeman
Activation of the Erk Mitogen-activated Protein Kinase Pathway Stimulates Neuroendocrine Differentiation in LNCaP Cells Independently of Cell Cycle Withdrawal and STAT3 Phosphorylation
Cancer Res., March 1, 2002; 62(5): 1549 - 1554.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. A. Moffatt, W. U. Johannes, T. E. Hedlund, and G. J. Miller
Growth Inhibitory Effects of 1{alpha}, 25-Dihydroxyvitamin D3 Are Mediated by Increased Levels of p21 in the Prostatic Carcinoma Cell Line ALVA-31
Cancer Res., October 1, 2001; 61(19): 7122 - 7129.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Prudencio, N. Akutsu, N. Benlimame, T. Wang, Y. Bastien, R. Lin, M. J. Black, M. A. Alaoui-Jamali, and J. H. White
Action of Low Calcemic 1{{alpha}},25-Dihydroxyvitamin D3 Analogue EB1089 in Head and Neck Squamous Cell Carcinoma
J Natl Cancer Inst, May 16, 2001; 93(10): 745 - 753.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Masood, S. Nagpal, T. Zheng, J. Cai, A. Tulpule, D. L. Smith, and P. S. Gill
Kaposi sarcoma is a therapeutic target for vitamin D3 receptor agonist
Blood, November 1, 2000; 96(9): 3188 - 3194.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Bratland, K. Risberg, G. M. Mælandsmo, K. B. Gützkow, O. E. Olsen, A. Moghaddam, M.-y. Wang, C. M. Hansen, H. K. Blomhoff, J. P. Berg, et al.
Expression of a Novel Factor, com1, Is Regulated by 1,25-Dihydroxyvitamin D3 in Breast Cancer Cells
Cancer Res., October 1, 2000; 60(19): 5578 - 5583.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
L. M. Butler, D. B. Agus, H. I. Scher, B. Higgins, A. Rose, C. Cordon-Cardo, H. T. Thaler, R. A. Rifkind, P. A. Marks, and V. M. Richon
Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Suppresses the Growth of Prostate Cancer Cells in Vitro and in Vivo
Cancer Res., September 1, 2000; 60(18): 5165 - 5170.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
X.-Y. Zhao, D. M. Peehl, N. M. Navone, and D. Feldman
1{alpha},25-Dihydroxyvitamin D3 Inhibits Prostate Cancer Cell Growth by Androgen-Dependent and Androgen-Independent Mechanisms
Endocrinology, July 1, 2000; 141(7): 2548 - 2556.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. R. Qadan, C. M. Perez-Stable, R. H. Schwall, K. L. Burnstein, R. C. Ostenson, G. A. Howard, and B. A. Roos
Hepatocyte Growth Factor and Vitamin D Cooperatively Inhibit Androgen-Unresponsive Prostate Cancer Cell Lines
Endocrinology, July 1, 2000; 141(7): 2567 - 2573.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Wang, W. Yang, M. S. Uytingco, S. Christakos, and R. Wieder
1,25-Dihydroxyvitamin D3 and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death
Cancer Res., April 1, 2000; 60(7): 2040 - 2048.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
S. E. Blutt, T. C. Polek, L. V. Stewart, M. W. Kattan, and N. L. Weigel
A Calcitriol Analogue, EB1089, Inhibits the Growth of LNCaP Tumors in Nude Mice
Cancer Res., February 1, 2000; 60(4): 779 - 782.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
D. Feldman, X.-Y. Zhao, and A. V. Krishnan
Editorial/Mini-Review: Vitamin D and Prostate Cancer
Endocrinology, January 1, 2000; 141(1): 5 - 9.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
S. E. Blutt, T. J. McDonnell, T. C. Polek, and N. L. Weigel
Calcitriol-Induced Apoptosis in LNCaP Cells Is Blocked By Overexpression of Bcl-2
Endocrinology, January 1, 2000; 141(1): 10 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Habuchi, T. Suzuki, R. Sasaki, L. Wang, K. Sato, S. Satoh, T. Akao, N. Tsuchiya, N. Shimoda, Y. Wada, et al.
Association of Vitamin D Receptor Gene Polymorphism with Prostate Cancer and Benign Prostatic Hyperplasia in a Japanese Population
Cancer Res., January 1, 2000; 60(2): 305 - 308.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
L. H. Ly, X.-Y. Zhao, L. Holloway, and D. Feldman
Liarozole Acts Synergistically with 1{alpha},25-Dihydroxyvitamin D3 to Inhibit Growth of DU 145 Human Prostate Cancer Cells by Blocking 24-Hydroxylase Activity
Endocrinology, May 1, 1999; 140(5): 2071 - 2076.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
X.-Y. Zhao, L. H. Ly, D. M. Peehl, and D. Feldman
Induction of Androgen Receptor by 1{alpha},25-Dihydroxyvitamin D3 and 9-cis Retinoic Acid in LNCaP Human Prostate Cancer Cells
Endocrinology, March 1, 1999; 140(3): 1205 - 1212.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
K. A. Moffatt, W. U. Johannes, and G. J. Miller
1{{alpha}},25-Dihydroxyvitamin D3 and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines
Clin. Cancer Res., March 1, 1999; 5(3): 695 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
E. Ruijter, C. van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken
Molecular Genetics and Epidemiology of Prostate Carcinoma
Endocr. Rev., February 1, 1999; 20(1): 22 - 45.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
D. L. McCormick, K. V. N. Rao, V. E. Steele, R. A. Lubet, G. J. Kelloff, and M. C. Bosland
Chemoprevention of Rat Prostate Carcinogenesis by 9-cis-Retinoic Acid
Cancer Res., February 1, 1999; 59(3): 521 - 524.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. J. Russell, S. Bennett, and P. Stricker
Growth factor involvement in progression of prostate cancer
Clin. Chem., April 1, 1998; 44(4): 705 - 723.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
S.-H. Zhuang and K. L. Burnstein
Antiproliferative Effect of 1{alpha},25-Dihydroxyvitamin D3 in Human Prostate Cancer Cell Line LNCaP Involves Reduction of Cyclin-Dependent Kinase 2 Activity and Persistent G1 Accumulation
Endocrinology, March 1, 1998; 139(3): 1197 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
X.-Y. Zhao, L. H. Ly, D. M. Peehl, and D. Feldman
1{alpha},25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent
Endocrinology, August 1, 1997; 138(8): 3290 - 3298.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Zou, M. G. Elgort, and E. A. Allegretto
Retinoid X Receptor (RXR) Ligands Activate the Human 25-Hydroxyvitamin D3-24-hydroxylase Promoter via RXR Heterodimer Binding to Two Vitamin D-responsive Elements and Elicit Additive Effects with 1,25-Dihydroxyvitamin D3
J. Biol. Chem., July 25, 1997; 272(30): 19027 - 19034.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society